Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $20.89.

Several research firms recently commented on YMAB. Wedbush reiterated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, January 10th. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares during the period. Intech Investment Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth approximately $133,000. SG Americas Securities LLC purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at $178,000. Finally, Empire Financial Management Company LLC purchased a new position in shares of Y-mAbs Therapeutics during the third quarter worth approximately $210,000. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $6.18 on Friday. The firm has a 50-day moving average of $9.60 and a 200-day moving average of $11.96. Y-mAbs Therapeutics has a one year low of $6.01 and a one year high of $20.90. The company has a market cap of $276.80 million, a P/E ratio of -11.44 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. During the same quarter last year, the business posted ($0.18) EPS. As a group, research analysts expect that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.